AccessibilityHelpAbout Us
Medicenna Therapeutics logo

Medicenna Therapeutics(TSX) MDNA

Market CapCA$31.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-85%
5 Year-87%
1 Year-57%
1 Month-14%
CA$0.40
-1.24%
-0.01Today
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 0.412026-09-25
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.71%CAD 0.432026-09-18
1 month-13.83%CAD 0.472026-08-26
3 month+0%CAD 0.412026-06-26
Year to date-55.98%CAD 0.922025-12-31
1 year-56.91%CAD 0.942025-09-25
3 year-1.22%CAD 0.412023-09-26
5 year-87.3%CAD 3.192021-09-24
Since inception-85%CAD 2.702017-03-08

Medicenna Therapeutics Financials at a Glance

Market Cap

CA$31.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$18.56M

EPS (TTM)

-CA$0.22

P/E Ratio

-1.84

Dividend

CA$0.00

Beta (Volatility)

1.05 (Average)

Price

CA$0.40

Volume

1,759

Open

CA$0.41

Previous Close

CA$0.41

Daily Range

CA$0.40 - CA$0.41

52-Week Range

CA$0.34 - CA$1.97

Estimated Earnings Date

Nov 12, 2026

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is an innovative immunotherapy company dedicated to developing and commercializing Superkines and "empowered Superkines" for cancer treatment and other diseases. The company is advancing its lead candidate, MDNA55, through clinical trials, while also exploring a diverse pipeline of therapeutic candidates.

Products and Services
  • MDNA55: An interleukin-4 empowered cytokine for glioblastoma treatment
  • MDNA11: An improved IL-2 variant targeting cancer immune responses
  • BiSKITs platform: Custom-engineered Superkines for various therapeutic applications
Growth Outlook
  • MDNA55 has completed Phase IIb trials, showing promising results for glioblastoma
  • Pipeline includes multiple candidates targeting both cancer and autoimmune diseases
  • Strategic partnerships may enhance development and commercialization opportunities
Financial Highlights
  • Recent quarterly net income of -$5.08 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $5.69 million as of June 30, 2026
  • Trailing twelve months (TTM) cash flow from operations indicates significant investment in growth
Medicenna Therapeutics Corp. operates in the biotechnology sector, focusing on innovative therapies that leverage the body's immune system to combat diseases. The company's lead product, MDNA55, has shown potential in clinical trials, particularly for treating recurrent glioblastoma, a challenging form of brain cancer. The diverse pipeline, including MDNA11 and other candidates, positions Medicenna to address various therapeutic needs in oncology and autoimmune disorders. The growth outlook remains robust, with the successful completion of clinical trials and the potential for strategic partnerships to accelerate development. Financially, the company is in a phase of significant investment, as evidenced by the recent quarterly net income figures, which reflect ongoing research and development efforts. The current cash position provides a foundation for continued operations and exploration of new opportunities in the immunotherapy landscape.
AI Generated • Sep 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-360.29%

Return on Capital

-911.57%

Return on Assets

-225.03%

Earnings Yield

-54.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$31.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.62M

Volume

1.76K

Avg. Volume

47.31K

Financials (TTM)

Gross Profit

-CA$75.00K

Operating Income

-CA$23.65M

EBITDA

-CA$22.99M

Operating Cash Flow

-CA$18.81M

Capital Expenditure

CA$9.44M

Free Cash Flow

-CA$14.33M

Cash & ST Invst.

CA$5.69M

Total Debt

CA$104.00K

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Q12026-06-30N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.16-62.7%
20242024-03-31CAD -0.37135.6%
20252025-03-31CAD -0.15-57.9%
20262026-03-31CAD -0.2243.7%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-302.0%
Q32025-12-3110.6%
Q42026-03-312.9%
Q12026-06-30-15.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$17.00K

+10.5%

Gross Margin

0.00%

N/A

Market Cap

CA$31.44MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.10M

N/A

Employees

15

N/A

Net Income

-CA$5.08M

-3.1%

EBITDA

-CA$5.43M

+1.0%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

CA$5.69M

-72.2%

Total Debt

CA$104.00K

-35.8%

Accounts Receivable

CA$1.52M

+29.9%

Inventory

CA$0.00

N/A

Long Term Debt

CA$33.00K

-68.3%

Short Term Debt

CA$71.00K

+22.4%

Return on Assets

-2.25%

N/A

Return on Invested Capital

-13.45%

N/A

Free Cash Flow

-CA$4.43M

-24.9%

Operating Cash Flow

-CA$4.43M

-24.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SVA.TOSernova Corp.
CA$0.09+0.00%
MIR.VMedMira Inc.
CA$0.07-7.14%
ZEN.VZentek Ltd.
CA$0.74+0.00%
COV.VCovalon Technologies Ltd.
CA$4.30+1.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$230.13+2.25%
NUNu Holdings
$12.47-8.28%
INTCIntel
$115.45-6.14%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$35.09+8.20%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at CA$0.40 per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between CA$0.34 and CA$1.97.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$104.00K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$5.69M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services